Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) EBIT Margin (2016 - 2025)

Dexcom (DXCM) has disclosed EBIT Margin for 16 consecutive years, with 25.64% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 868.0% to 25.64% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 19.56% through Dec 2025, up 468.0% year-over-year, with the annual reading at 19.56% for FY2025, 468.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 25.64% at Dexcom, up from 20.05% in the prior quarter.
  • The five-year high for EBIT Margin was 25.64% in Q4 2025, with the low at 0.09% in Q4 2021.
  • Average EBIT Margin over 5 years is 14.78%, with a median of 15.56% recorded in 2022.
  • The sharpest move saw EBIT Margin crashed -1819bps in 2021, then skyrocketed 1530bps in 2022.
  • Over 5 years, EBIT Margin stood at 0.09% in 2021, then skyrocketed by 17800bps to 15.38% in 2022, then skyrocketed by 36bps to 20.97% in 2023, then fell by -19bps to 16.96% in 2024, then skyrocketed by 51bps to 25.64% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 25.64%, 20.05%, and 18.37% for Q4 2025, Q3 2025, and Q2 2025 respectively.